Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 25;159(8):1580–1591. doi: 10.1097/j.pain.0000000000001246

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 4. — Effects of exogenous prostatic acid phosphatase (PAP) on the mechanical threshold in resiniferatoxin (RTX) neuropathy. (A–D) Prostatic acid phosphatase was replenished with purified human PAP (hPAP) administered through either the intraperitoneal (i.p.) injection (A) or intrathecal (i.t.) lumbar puncture (B–D) route in different bioactive doses. The arrow indicates the time point of hPAP administration. The effect of hPAP on the mechanical threshold was examined through von Frey monofilament tests using up-and-down algorithms at 1 hour (h1), 2 hours (h2), 4 hours (h4), 6 hours (h6), 1 day (D1), 2 days (D2), 3 days (D3), 4 days (D4), and 7 days (D7) after hPAP administration. (A) The diagram illustrates the effects of 9 U of hPAP on the mechanical threshold (filled circle, n = 6) in comparison with those of saline treatment (sham group; open circle, n = 8) through the i.p. route. (B–D) The graphs show the analgesic effects of hPAP administered at doses of 0.3 U (B, n = 5), 3 U (C, n = 6), and 9 U (D, n = 5) through the i.t. route in RTX neuropathy (filled circle) in comparison with sham group (open circle, n = 6). *P < 0.05, **P < 0.01, and ***P < 0.001: pairing repeated-measures ANOVA followed the Bonferroni post hoc test comparing values before and after hPAP administration. #P < 0.05, ##P < 0.01, and ###P < 0.001: nonpairing repeated-measures ANOVA followed the Bonferroni post hoc test between hPAP and sham group. ANOVA, analysis of variance.